Advertisement

Index by author

November 01, 1993; Volume 267,Issue 2

A

  1. Abercrombie, E D

    1. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
      D Jackson, E D Abercrombie and M J Zigmond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 912-918;

  2. Adams, R

    1. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
      R W Kuncl, D B Drachman, R Adams and M Lehar
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 582-589;

  3. Adler, M W

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

  4. Alexandre, I

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

  5. Arimura, A

    1. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.
      W A Banks, A J Kastin, G Komaki and A Arimura
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 690-696;

  6. Arnould, T

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

B

  1. Bakry, N

    1. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin.
      L L Simpson, J A Coffield and N Bakry
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 720-727;

  2. Banks, W A

    1. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.
      W A Banks, A J Kastin, G Komaki and A Arimura
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 690-696;

  3. Barbanti, G

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  4. Bell-Quilley, C P

    1. Renovascular actions of angiotensin II in the isolated kidney of the rat: relationship to lipoxygenases.
      C P Bell-Quilley, Y S Lin, S D Hilchey, E D Drugge and J C McGiff
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 676-682;

  5. Bend, J R

    1. Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.
      L C Knickle, C D Webb, A A House and J R Bend
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 758-764;

  6. Bergman, J

    1. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
      S Rosenzweig-Lipson and J Bergman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 765-775;

  7. Biaggioni, I

    1. Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets.
      S Paul, B Kurunwune and I Biaggioni
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 838-843;

  8. Bigelow, G E

    1. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 624-634;

  9. Biggio, G

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  10. Bilsky, E J

    1. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;

  11. Black, A

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  12. Blake, D R

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  13. Blom-Roosemalen, M C

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

  14. Blumberg, P M

    1. Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat.
      A Szallasi, C Goso, P M Blumberg and S Manzini
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 728-733;

  15. Bonhaus, D W

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  16. Bonin, H

    1. Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
      T Suzuki, F Nantel, H Bonin, M Valiquette and M Bouvier
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 785-790;

  17. Bousley, R

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  18. Bouvier, M

    1. Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
      T Suzuki, F Nantel, H Bonin, M Valiquette and M Bouvier
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 785-790;

  19. Breimer, D D

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

  20. Bryan-Lluka, L J

    1. Types A and B monoamine oxidase contribute to the metabolism of norepinephrine in perfused lungs of rats.
      N N Westwood and L J Bryan-Lluka
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 815-821;

  21. Burch, R M

    1. NPC 15669 reduces mortality associated with sepsis in rats.
      L Noronha-Blob, V C Lowe, L Otterbein, L Steranka and R M Burch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 664-669;

  22. Burczynski, F J

    1. Facilitated dissociation of albumin-fatty acid complexes by rat hepatocytes.
      F J Burczynski, J B Moran and Z S Cai
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 714-719;

  23. Burke, T F

    1. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
      S S Negus, T F Burke, F Medzihradsky and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 896-903;

  24. Bush, L G

    1. Differential regulation of neuropeptide Y systems in limbic structures of the rat.
      L P Midgley, L G Bush, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 707-713;

  25. Bussiere, J L

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

C

  1. Cai, Z S

    1. Facilitated dissociation of albumin-fatty acid complexes by rat hepatocytes.
      F J Burczynski, J B Moran and Z S Cai
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 714-719;

  2. Chang, K J

    1. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.
      K J Chang, G C Rigdon, J L Howard and R W McNutt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 852-857;
    2. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;
    3. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    4. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
      L A Dykstra, G M Schoenbaum, J Yarbrough, R McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 875-882;
    5. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat.
      P H Lee, R W McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 883-887;
    6. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  3. Chen, I W

    1. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
      J H Lin, I W Chen, F A deLuna and M Hichens
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 670-675;

  4. Chen, J

    1. A study of the dose dependency of a glycine receptor antagonist in focal ischemia.
      J Chen, S Graham, F Moroni and R Simon
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 937-941;

  5. Chiu, A T

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  6. Cho, H L

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  7. Chu, T C

    1. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
      M Ogidigben, T C Chu and D E Potter
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 822-827;

  8. Cockerham, S L

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  9. Coffield, J A

    1. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin.
      L L Simpson, J A Coffield and N Bakry
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 720-727;

  10. Comer, S D

    1. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    2. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  11. Concas, A

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  12. Cornicelli, J

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  13. Culman, J

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

D

  1. Datz, F L

    1. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
      K A Morton, B J Jones, M H Sohn, F L Datz and R E Lynch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 697-702;

  2. Dazzi, L

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  3. de Boer, A G

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

  4. De Costa, B R

    1. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    2. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  5. deLuna, F A

    1. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
      J H Lin, I W Chen, F A deLuna and M Hichens
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 670-675;

  6. DeSouza, A

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  7. Diéz Marques, M L

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

  8. Dillard, R D

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  9. Divish, B J

    1. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
      D M Pollock, B J Divish, J S Polakowski and T J Opgenorth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 657-663;

  10. Drachman, D B

    1. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
      R W Kuncl, D B Drachman, R Adams and M Lehar
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 582-589;

  11. Drugge, E D

    1. Renovascular actions of angiotensin II in the isolated kidney of the rat: relationship to lipoxygenases.
      C P Bell-Quilley, Y S Lin, S D Hilchey, E D Drugge and J C McGiff
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 676-682;

  12. Duncia, J V

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  13. Duque, I

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

  14. Dykstra, L A

    1. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
      L A Dykstra, G M Schoenbaum, J Yarbrough, R McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 875-882;

E

  1. Eberle-Wang, K

    1. Serotonin-induced muscle contraction in rat stomach fundus is mediated by a G alpha z-like guanine nucleotide binding protein.
      H Y Wang, K Eberle-Wang, K J Simansky and E Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1002-1011;

  2. Eglen, R M

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  3. Eisenstein, T K

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

  4. Essenburg, A

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

F

  1. Falotico, R

    1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
      L B Katz, E C Giardino, J J Salata, J B Moore and R Falotico
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 648-656;

  2. Fermini, B

    1. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.
      Z Wang, B Fermini and S Nattel
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 575-581;

  3. Fraser, D G

    1. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig.
      J F Regal, D G Fraser and C A Toth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 979-988;

  4. Fredholm, B B

    1. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices.
      S Jin, B Johansson and B B Fredholm
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 801-808;

  5. Frelinger, A L

    1. Prevention of experimental carotid artery thrombosis by applaggin.
      W E Rote, D X Mu, R A Roncinske, A L Frelinger and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 809-814;

  6. Friedman, E

    1. Serotonin-induced muscle contraction in rat stomach fundus is mediated by a G alpha z-like guanine nucleotide binding protein.
      H Y Wang, K Eberle-Wang, K J Simansky and E Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1002-1011;

  7. Friedman, H

    1. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila.
      T W Klein, C Newton, R Widen and H Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 635-640;

  8. Friedman, Z Y

    1. Tamoxifen and vanadate synergize in causing accumulation of polyphosphoinositides in GH4C1 membranes.
      Z Y Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 617-623;

  9. Fujitani, Y

    1. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.
      Y Fujitani, H Ueda, T Okada, Y Urade and H Karaki
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 683-689;

G

  1. Garrett, N

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  2. Giachetti, A

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  3. Giardino, E C

    1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
      L B Katz, E C Giardino, J J Salata, J B Moore and R Falotico
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 648-656;

  4. Gibb, J W

    1. Differential regulation of neuropeptide Y systems in limbic structures of the rat.
      L P Midgley, L G Bush, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 707-713;

  5. Giuliani, S

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  6. Goldstein, A

    1. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
      J Stagsted, T Hansen, R A Roth, A Goldstein and L Olsson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 997-1001;

  7. Gonzalez, F J

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

  8. Gonzalez-Rubio, M

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

  9. Goso, C

    1. Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat.
      A Szallasi, C Goso, P M Blumberg and S Manzini
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 728-733;

  10. Graham, S

    1. A study of the dose dependency of a glycine receptor antagonist in focal ischemia.
      J Chen, S Graham, F Moroni and R Simon
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 937-941;

H

  1. Hansen, T

    1. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
      J Stagsted, T Hansen, R A Roth, A Goldstein and L Olsson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 997-1001;

  2. Hanson, G R

    1. Differential regulation of neuropeptide Y systems in limbic structures of the rat.
      L P Midgley, L G Bush, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 707-713;

  3. Hatakeyama, K

    1. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice.
      M Hoshiga, K Hatakeyama, M Watanabe, M Shimada and H Kagamiyama
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 971-978;

  4. Hichens, M

    1. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
      J H Lin, I W Chen, F A deLuna and M Hichens
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 670-675;

  5. Hilchey, S D

    1. Renovascular actions of angiotensin II in the isolated kidney of the rat: relationship to lipoxygenases.
      C P Bell-Quilley, Y S Lin, S D Hilchey, E D Drugge and J C McGiff
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 676-682;

  6. Hirsh, J K

    1. Aminopyridine block of potassium channels in mouse neuroblastoma cells.
      J K Hirsh and F N Quandt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 604-611;

  7. Hoenicke, E M

    1. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  8. Hollenberg, P F

    1. Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
      H Kim, D Putt, S Reddy, P F Hollenberg and R F Novak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 927-936;

  9. Holmes, A

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  10. Homan, R

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  11. Hoshiga, M

    1. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice.
      M Hoshiga, K Hatakeyama, M Watanabe, M Shimada and H Kagamiyama
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 971-978;

  12. Houbion, A

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

  13. House, A A

    1. Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.
      L C Knickle, C D Webb, A A House and J R Bend
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 758-764;

  14. Howard, J L

    1. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.
      K J Chang, G C Rigdon, J L Howard and R W McNutt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 852-857;

  15. Hurni, M A

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

I

  1. Ikegami, Y

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  2. Imaoka, S

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

J

  1. Jackson, D

    1. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
      D Jackson, E D Abercrombie and M J Zigmond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 912-918;

  2. Jakeman, L B

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  3. Janssens, D

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

  4. Jin, S

    1. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices.
      S Jin, B Johansson and B B Fredholm
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 801-808;

  5. Johansson, B

    1. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices.
      S Jin, B Johansson and B B Fredholm
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 801-808;

  6. Jones, B J

    1. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
      K A Morton, B J Jones, M H Sohn, F L Datz and R E Lynch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 697-702;

K

  1. Kagamiyama, H

    1. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice.
      M Hoshiga, K Hatakeyama, M Watanabe, M Shimada and H Kagamiyama
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 971-978;

  2. Karaki, H

    1. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.
      Y Fujitani, H Ueda, T Okada, Y Urade and H Karaki
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 683-689;

  3. Kashihara, Y

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  4. Kastin, A J

    1. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.
      W A Banks, A J Kastin, G Komaki and A Arimura
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 690-696;

  5. Katz, L B

    1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
      L B Katz, E C Giardino, J J Salata, J B Moore and R Falotico
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 648-656;

  6. Kieft, K

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  7. Kim, C S

    1. Transport of 2,4,5-trichlorophenoxyacetic acid across the blood-cerebrospinal fluid barrier of the rabbit.
      C S Kim and J B Pritchard
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 751-757;

  8. Kim, H

    1. Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
      H Kim, D Putt, S Reddy, P F Hollenberg and R F Novak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 927-936;

  9. Kim, H Y

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

  10. Kimura, S

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

  11. Klein, T W

    1. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila.
      T W Klein, C Newton, R Widen and H Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 635-640;

  12. Kline, J A

    1. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
      J A Kline, C A Tomaszewski, J D Schroeder and R M Raymond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 744-750;

  13. Knickle, L C

    1. Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.
      L C Knickle, C D Webb, A A House and J R Bend
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 758-764;

  14. Komaki, G

    1. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.
      W A Banks, A J Kastin, G Komaki and A Arimura
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 690-696;

  15. Krause, B R

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  16. Kuncl, R W

    1. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
      R W Kuncl, D B Drachman, R Adams and M Lehar
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 582-589;

  17. Kurunwune, B

    1. Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets.
      S Paul, B Kurunwune and I Biaggioni
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 838-843;

L

  1. Lee, P H

    1. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat.
      P H Lee, R W McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 883-887;

  2. Lehar, M

    1. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors.
      R W Kuncl, D B Drachman, R Adams and M Lehar
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 582-589;

  3. Liebson, I A

    1. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 624-634;

  4. Lin, J H

    1. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
      J H Lin, I W Chen, F A deLuna and M Hichens
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 670-675;

  5. Lin, Y S

    1. Renovascular actions of angiotensin II in the isolated kidney of the rat: relationship to lipoxygenases.
      C P Bell-Quilley, Y S Lin, S D Hilchey, E D Drugge and J C McGiff
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 676-682;

  6. Loury, D N

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  7. Lowe, V C

    1. NPC 15669 reduces mortality associated with sepsis in rats.
      L Noronha-Blob, V C Lowe, L Otterbein, L Steranka and R M Burch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 664-669;

  8. Lucchesi, B R

    1. Prevention of experimental carotid artery thrombosis by applaggin.
      W E Rote, D X Mu, R A Roncinske, A L Frelinger and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 809-814;

  9. Lynch, R E

    1. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
      K A Morton, B J Jones, M H Sohn, F L Datz and R E Lynch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 697-702;

M

  1. Maas, K

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

  2. Maciocco, E

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  3. Maggi, C A

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  4. Manzini, S

    1. Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat.
      A Szallasi, C Goso, P M Blumberg and S Manzini
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 728-733;

  5. Mapp, P I

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  6. Mascia, M P

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  7. McCormick, J

    1. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;

  8. McGiff, J C

    1. Renovascular actions of angiotensin II in the isolated kidney of the rat: relationship to lipoxygenases.
      C P Bell-Quilley, Y S Lin, S D Hilchey, E D Drugge and J C McGiff
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 676-682;

  9. McIvor, R S

    1. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate.
      D B Vinh and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 989-996;

  10. McNutt, R

    1. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
      L A Dykstra, G M Schoenbaum, J Yarbrough, R McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 875-882;

  11. McNutt, R W

    1. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.
      K J Chang, G C Rigdon, J L Howard and R W McNutt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 852-857;
    2. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;
    3. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    4. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat.
      P H Lee, R W McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 883-887;
    5. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  12. Medzihradsky, F

    1. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
      S S Negus, T F Burke, F Medzihradsky and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 896-903;

  13. Michiels, C

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

  14. Midgley, L P

    1. Differential regulation of neuropeptide Y systems in limbic structures of the rat.
      L P Midgley, L G Bush, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 707-713;

  15. Miyamoto, M

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  16. Moore, J B

    1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
      L B Katz, E C Giardino, J J Salata, J B Moore and R Falotico
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 648-656;

  17. Moran, J B

    1. Facilitated dissociation of albumin-fatty acid complexes by rat hepatocytes.
      F J Burczynski, J B Moran and Z S Cai
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 714-719;

  18. Morimoto, K

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  19. Moroni, F

    1. A study of the dose dependency of a glycine receptor antagonist in focal ischemia.
      J Chen, S Graham, F Moroni and R Simon
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 937-941;

  20. Morton, K A

    1. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
      K A Morton, B J Jones, M H Sohn, F L Datz and R E Lynch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 697-702;

  21. Mosberg, H I

    1. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    2. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  22. Mu, D X

    1. Prevention of experimental carotid artery thrombosis by applaggin.
      W E Rote, D X Mu, R A Roncinske, A L Frelinger and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 809-814;

N

  1. Nagelkerke, J F

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

  2. Nakao, K

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  3. Nantel, F

    1. Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
      T Suzuki, F Nantel, H Bonin, M Valiquette and M Bouvier
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 785-790;

  4. Nattel, S

    1. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.
      Z Wang, B Fermini and S Nattel
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 575-581;

  5. Negus, S S

    1. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
      S S Negus, T F Burke, F Medzihradsky and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 896-903;

  6. Newton, C

    1. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila.
      T W Klein, C Newton, R Widen and H Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 635-640;

  7. Noach, A B

    1. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy.
      M A Hurni, A B Noach, M C Blom-Roosemalen, A G de Boer, J F Nagelkerke and D D Breimer
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 942-950;

  8. Noguchi, S

    1. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats.
      S Noguchi, Y Kashihara, Y Ikegami, K Morimoto, M Miyamoto and K Nakao
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 919-926;

  9. Noronha-Blob, L

    1. NPC 15669 reduces mortality associated with sepsis in rats.
      L Noronha-Blob, V C Lowe, L Otterbein, L Steranka and R M Burch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 664-669;

  10. Novak, R F

    1. Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
      H Kim, D Putt, S Reddy, P F Hollenberg and R F Novak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 927-936;

O

  1. Obenchain, R L

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  2. Ogawa, H

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

  3. Ogidigben, M

    1. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
      M Ogidigben, T C Chu and D E Potter
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 822-827;

  4. Okada, T

    1. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.
      Y Fujitani, H Ueda, T Okada, Y Urade and H Karaki
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 683-689;

  5. Olson, R E

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  6. Olsson, L

    1. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
      J Stagsted, T Hansen, R A Roth, A Goldstein and L Olsson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 997-1001;

  7. Ongini, E

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  8. Opgenorth, T J

    1. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
      D M Pollock, B J Divish, J S Polakowski and T J Opgenorth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 657-663;

  9. Otterbein, L

    1. NPC 15669 reduces mortality associated with sepsis in rats.
      L Noronha-Blob, V C Lowe, L Otterbein, L Steranka and R M Burch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 664-669;

P

  1. Patacchini, R

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  2. Paul, S

    1. Caffeine withdrawal: apparent heterologous sensitization to adenosine and prostacyclin actions in human platelets.
      S Paul, B Kurunwune and I Biaggioni
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 838-843;

  3. Pechous, P A

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  4. Polak, J M

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  5. Polakowski, J S

    1. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
      D M Pollock, B J Divish, J S Polakowski and T J Opgenorth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 657-663;

  6. Pollock, D M

    1. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
      D M Pollock, B J Divish, J S Polakowski and T J Opgenorth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 657-663;

  7. Porreca, F

    1. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;

  8. Potter, D E

    1. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
      M Ogidigben, T C Chu and D E Potter
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 822-827;

  9. Preston, K L

    1. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 624-634;

  10. Pritchard, J B

    1. Transport of 2,4,5-trichlorophenoxyacetic acid across the blood-cerebrospinal fluid barrier of the rabbit.
      C S Kim and J B Pritchard
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 751-757;

  11. Putt, D

    1. Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
      H Kim, D Putt, S Reddy, P F Hollenberg and R F Novak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 927-936;

Q

  1. Qadri, F

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

  2. Quandt, F N

    1. Aminopyridine block of potassium channels in mouse neuroblastoma cells.
      J K Hirsh and F N Quandt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 604-611;

  3. Quartara, L

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

R

  1. Rascher, W

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

  2. Raymond, R M

    1. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
      J A Kline, C A Tomaszewski, J D Schroeder and R M Raymond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 744-750;

  3. Reddy, S

    1. Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
      H Kim, D Putt, S Reddy, P F Hollenberg and R F Novak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 927-936;

  4. Regal, J F

    1. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig.
      J F Regal, D G Fraser and C A Toth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 979-988;

  5. Remacle, J

    1. Effects of naftidrofuryl on hypoxia-induced activation and mortality of human endothelial cells.
      C Michiels, T Arnould, D Janssens, I Alexandre, A Houbion and J Remacle
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 904-911;

  6. Riekkinen, M

    1. Effects of nicotine on neocortical electrical activity in rats.
      P Riekkinen, M Riekkinen and J Sirviö
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 776-784;

  7. Riekkinen, P

    1. Effects of nicotine on neocortical electrical activity in rats.
      P Riekkinen, M Riekkinen and J Sirviö
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 776-784;

  8. Rigdon, G C

    1. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.
      K J Chang, G C Rigdon, J L Howard and R W McNutt
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 852-857;

  9. Rodriguez Puyol, D

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

  10. Rodriguez Puyol, M

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

  11. Rogers, T J

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

  12. Rojavin, M

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

  13. Rominger, D H

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  14. Roncinske, R A

    1. Prevention of experimental carotid artery thrombosis by applaggin.
      W E Rote, D X Mu, R A Roncinske, A L Frelinger and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 809-814;

  15. Rosenzweig-Lipson, S

    1. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
      S Rosenzweig-Lipson and J Bergman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 765-775;

  16. Rote, W E

    1. Prevention of experimental carotid artery thrombosis by applaggin.
      W E Rote, D X Mu, R A Roncinske, A L Frelinger and B R Lucchesi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 809-814;

  17. Roth, R A

    1. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
      J Stagsted, T Hansen, R A Roth, A Goldstein and L Olsson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 997-1001;

  18. Rovero, P

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

  19. Ruiz, P

    1. Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells.
      I Duque, M Rodriguez Puyol, P Ruiz, M Gonzalez-Rubio, M L Diéz Marques and D Rodriguez Puyol
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 612-616;

S

  1. Sable, A I

    1. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;

  2. Salata, J J

    1. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
      L B Katz, E C Giardino, J J Salata, J B Moore and R Falotico
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 648-656;

  3. Salmon, M

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  4. Santoro, G

    1. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain.
      A Concas, G Santoro, M P Mascia, E Maciocco, L Dazzi, E Ongini and G Biggio
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 844-851;

  5. Schoenbaum, G M

    1. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
      L A Dykstra, G M Schoenbaum, J Yarbrough, R McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 875-882;

  6. Schroeder, J D

    1. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
      J A Kline, C A Tomaszewski, J D Schroeder and R M Raymond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 744-750;

  7. Sekerke, C

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  8. Shaw-Hes, M K

    1. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
      B R Krause, A Black, R Bousley, A Essenburg, J Cornicelli, A Holmes, R Homan, K Kieft, C Sekerke and M K Shaw-Hes
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 734-743;

  9. Shimada, M

    1. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice.
      M Hoshiga, K Hatakeyama, M Watanabe, M Shimada and H Kagamiyama
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 971-978;

  10. Silbaugh, S A

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  11. Simansky, K J

    1. Serotonin-induced muscle contraction in rat stomach fundus is mediated by a G alpha z-like guanine nucleotide binding protein.
      H Y Wang, K Eberle-Wang, K J Simansky and E Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1002-1011;

  12. Simon, R

    1. A study of the dose dependency of a glycine receptor antagonist in focal ischemia.
      J Chen, S Graham, F Moroni and R Simon
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 937-941;

  13. Simpson, L L

    1. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin.
      L L Simpson, J A Coffield and N Bakry
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 720-727;

  14. Sirviö, J

    1. Effects of nicotine on neocortical electrical activity in rats.
      P Riekkinen, M Riekkinen and J Sirviö
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 776-784;

  15. Snyder, D W

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  16. Sohn, M H

    1. Enrichment for metallothionein does not confer resistance to cisplatin in transfected NIH/3T3 cells.
      K A Morton, B J Jones, M H Sohn, F L Datz and R E Lynch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 697-702;

  17. Spaethe, S M

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  18. Stagsted, J

    1. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide.
      J Stagsted, T Hansen, R A Roth, A Goldstein and L Olsson
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 997-1001;

  19. Stengel, P W

    1. Bronchopulmonary actions of 1-(1,2,3,4-tetrahydro-1-naphthylenyl)-1H-imidazole, nitric acid salt (LY150310), a substituted imidazole, in the guinea pig.
      P W Stengel, R D Dillard, H L Cho, D W Snyder, S M Spaethe, P A Pechous, R L Obenchain, S L Cockerham and S A Silbaugh
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 596-603;

  20. Steranka, L

    1. NPC 15669 reduces mortality associated with sepsis in rats.
      L Noronha-Blob, V C Lowe, L Otterbein, L Steranka and R M Burch
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 664-669;

  21. Strain, E C

    1. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
      E C Strain, K L Preston, I A Liebson and G E Bigelow
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 624-634;

  22. Suzuki, T

    1. Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
      T Suzuki, F Nantel, H Bonin, M Valiquette and M Bouvier
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 785-790;

  23. Szabo, I

    1. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids.
      I Szabo, M Rojavin, J L Bussiere, T K Eisenstein, M W Adler and T J Rogers
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 703-706;

  24. Szallasi, A

    1. Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat.
      A Szallasi, C Goso, P M Blumberg and S Manzini
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 728-733;

T

  1. Tam, S W

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  2. Thalody, G P

    1. Differential attenuation of the responses to adenosine and methoxamine in isolated rabbit aorta.
      H L Wiener and G P Thalody
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 828-837;

  3. Timmermans, P B

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  4. To, Z

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  5. Tomaszewski, C A

    1. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.
      J A Kline, C A Tomaszewski, J D Schroeder and R M Raymond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 744-750;

  6. Toth, C A

    1. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig.
      J F Regal, D G Fraser and C A Toth
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 979-988;

  7. Turini, D

    1. Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors.
      S Giuliani, R Patacchini, G Barbanti, D Turini, P Rovero, L Quartara, A Giachetti and C A Maggi
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 590-595;

U

  1. Ueda, H

    1. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.
      Y Fujitani, H Ueda, T Okada, Y Urade and H Karaki
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 683-689;

  2. Unger, T

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

  3. Urade, Y

    1. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta.
      Y Fujitani, H Ueda, T Okada, Y Urade and H Karaki
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 683-689;

V

  1. Valiquette, M

    1. Cellular characterization of the pharmacological selectivity and tachyphylactic properties of denopamine for the human beta adrenergic receptors.
      T Suzuki, F Nantel, H Bonin, M Valiquette and M Bouvier
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 785-790;

  2. Vanderah, T

    1. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;

  3. Veltmar, A

    1. Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus.
      F Qadri, J Culman, A Veltmar, K Maas, W Rascher and T Unger
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 567-574;

  4. Vinh, D B

    1. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate.
      D B Vinh and R S McIvor
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 989-996;

W

  1. Walsh, D A

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  2. Wang, H Y

    1. Serotonin-induced muscle contraction in rat stomach fundus is mediated by a G alpha z-like guanine nucleotide binding protein.
      H Y Wang, K Eberle-Wang, K J Simansky and E Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1002-1011;

  3. Wang, Z

    1. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.
      Z Wang, B Fermini and S Nattel
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 575-581;

  4. Watanabe, M

    1. Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice.
      M Hoshiga, K Hatakeyama, M Watanabe, M Shimada and H Kagamiyama
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 971-978;

  5. Webb, C D

    1. Mechanism-based inactivation of cytochrome P450 1A1 by N-aralkyl-1-aminobenzotriazoles in guinea pig kidney in vivo and in vitro: minimal effects on metabolism of arachidonic acid by renal P450-dependent monooxygenases.
      L C Knickle, C D Webb, A A House and J R Bend
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 758-764;

  6. Wedlund, P J

    1. Identification of CYP2C23 expressed in rat kidney as an arachidonic acid epoxygenase.
      S Imaoka, P J Wedlund, H Ogawa, S Kimura, F J Gonzalez and H Y Kim
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 1012-1016;

  7. Westwood, N N

    1. Types A and B monoamine oxidase contribute to the metabolism of norepinephrine in perfused lungs of rats.
      N N Westwood and L J Bryan-Lluka
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 815-821;

  8. Wharton, J

    1. Microvascular substance P binding to normal and inflamed rat and human synovium.
      D A Walsh, M Salmon, P I Mapp, J Wharton, N Garrett, D R Blake and J M Polak
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 951-960;

  9. Widen, R

    1. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila.
      T W Klein, C Newton, R Widen and H Friedman
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 635-640;

  10. Wiener, H L

    1. Differential attenuation of the responses to adenosine and methoxamine in isolated rabbit aorta.
      H L Wiener and G P Thalody
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 828-837;

  11. Wild, K D

    1. Antinociceptive actions of BW373U86 in the mouse.
      K D Wild, J McCormick, E J Bilsky, T Vanderah, R W McNutt, K J Chang and F Porreca
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 858-865;

  12. Wong, E H

    1. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
      D W Bonhaus, D N Loury, L B Jakeman, Z To, A DeSouza, R M Eglen and E H Wong
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 961-970;

  13. Wong, P C

    1. EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
      P C Wong, J V Duncia, A T Chiu, R E Olson, D H Rominger, S W Tam and P B Timmermans
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 641-647;

  14. Woods, J H

    1. Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors.
      S D Comer, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 866-874;
    2. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
      S D Comer, E M Hoenicke, A I Sable, R W McNutt, K J Chang, B R De Costa, H I Mosberg and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 888-895;
    3. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
      S S Negus, T F Burke, F Medzihradsky and J H Woods
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 896-903;

Y

  1. Yarbrough, J

    1. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
      L A Dykstra, G M Schoenbaum, J Yarbrough, R McNutt and K J Chang
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 875-882;

Z

  1. Zalups, R K

    1. Influence of 2,3-dimercaptopropane-1-sulfonate (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the renal disposition of mercury in normal and uninephrectomized rats exposed to inorganic mercury.
      R K Zalups
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 791-800;

  2. Zigmond, M J

    1. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
      D Jackson, E D Abercrombie and M J Zigmond
      Journal of Pharmacology and Experimental Therapeutics November 1993, 267 (2) 912-918;
Back to top

In this issue